A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)

• Main Authors: Mario Valenti (Author), Luciano Ibba (Author), Ruggero Cascio Ingurgio (Author), Piergiorgio Malagoli (Author), Andrea Carugno (Author), Marco Campoli (Author), Carlo G. Carrera (Author), Francesca M. Gaiani (Author), Davide Strippoli (Author), Federica Mola (Author), Angelo V. Marzano (Author), Nicola Zerbinati (Author), Anna Minuti (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This st...